Israel's Ministry of Health has approved Amai Proteins' sweelin® as a novel food ingredient, clearing it for commercial use across more than 25 food and beverage categories. The ruling makes Israel the third market to greenlight sweelin® in under six months, following FDA GRAS status in the United States and clearance from Singapore's Food Agency earlier in 2026.

What the Ingredient Delivers

For food and beverage manufacturers, sweelin® addresses one of the industry's most persistent formulation challenges: cutting sugar without sacrificing taste or process compatibility. The precision-fermented sweet protein is derived from monellin—a compound found in the West African serendipity berry—and is on average 3,000 times sweeter than sucrose by weight, which means effective use levels are extremely small. Amai says the ingredient enables up to 70% sugar reduction across a wide range of applications, including confectionery, condiments, chewing gum, beverages, and dietary supplements, while remaining compatible with industrial food processing conditions.

Beyond sweetness, sweelin® carries a clinical distinction: Amai points to what it calls the world's first published human clinical study on a sweet protein, demonstrating the ingredient does not raise blood glucose, insulin, or GLP-1 levels. That profile positions sweelin® squarely within two of the hottest currents in food and beverage innovation—clean-label formulation and GLP-1-friendly product development, a segment drawing intense manufacturer and consumer interest as appetite-regulating medications reshape purchasing behavior.

Operator and Manufacturer Implications

"We are especially proud that sweelin® is the first sweet protein approved in Israel," said Dr. Amir Guttman, CEO of Amai Proteins. "As an Israeli company, we are excited to make this innovative ingredient available to local food and beverage manufacturers and help them develop healthier products without compromising on taste."

For manufacturers and product developers tracking alternative sweetener innovation, the pace of Amai's regulatory progress is notable. Three market approvals in six months signals a maturing commercialization pathway for precision-fermented sweet proteins—a category that until recently existed largely in research and pilot-scale settings. Brands formulating for sugar reduction in multiple geographies can now consider sweelin® within a single international compliance framework that spans the U.S., Singapore, and Israel.

The broader competitive context matters here. Sugar reduction remains a primary reformulation priority across foodservice and packaged goods as health-conscious consumers demand lower-sugar options that still taste good—a combination conventional high-intensity sweeteners have struggled to deliver without off-notes. Precision fermentation, which uses engineered microorganisms to produce specific proteins at scale, offers a production route that aligns with clean-label positioning in ways that synthetic sweeteners typically cannot. Operators and product developers following beverage reformulation strategies will want to track how early adopters leverage sweelin® in category-specific applications.

Amai is actively working with food and beverage manufacturers to bring sweelin®-containing products to market across its approved regions. The company's partnership pipeline, combined with its expanding regulatory footprint, suggests commercialized products could reach retail and foodservice shelves in the near term.

Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.